Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases

Journal of Medicinal Chemistry
Peng LiLawrence P Wennogle

Abstract

A diverse set of 3-aminopyrazolo[3,4-d]pyrimidinones was designed and synthesized. The structure-activity relationships of these polycyclic compounds as phosphodiesterase 1 (PDE1) inhibitors were studied along with their physicochemical and pharmacokinetic properties. Systematic optimizations of this novel scaffold culminated in the identification of a clinical candidate, (6aR,9aS)-2-(4-(6-fluoropyridin-2-yl)benzyl)-5-methyl-3-(phenylamino)-5,6a,7,8,9,9a-hexahydrocyclopenta[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4-(2H)-one phosphate (ITI-214), which exhibited picomolar inhibitory potency for PDE1, demonstrated excellent selectivity against all other PDE families and showed good efficacy in vivo. Currently, this investigational new drug is in Phase I clinical development and being considered for the treatment of several indications including cognitive deficits associated with schizophrenia and Alzheimer's disease, movement disorders, attention deficit and hyperactivity disorders, and other central nervous system (CNS) and non-CNS disorders.

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·J W Polli, R L Kincaid
Apr 1, 1990·Journal of Pediatric Gastroenterology and Nutrition·E DreizzenC Gaultier
Jan 1, 1988·Methods in Enzymology·J N Wells, J R Miller
Sep 1, 1987·Archives of Gerontology and Geriatrics·P S Goldman-Rakic
Feb 1, 1995·Protein Engineering·A C WallaceJ M Thornton
Aug 5, 1998·International Clinical Psychopharmacology·C A TammingaJ M Gold
Aug 12, 1999·Cellular and Molecular Life Sciences : CMLS·R KakkarR K Sharma
Aug 6, 2000·Acta Crystallographica. Section A, Foundations of Crystallography
Nov 3, 2001·Science·P Greengard
Sep 19, 2002·Chemical & Pharmaceutical Bulletin·Hirokazu SuzukiHiroyuki Sawanishi
May 1, 2004·Psychopharmacology·Patricia S Goldman-RakicGraham V Williams
Jul 21, 2004·Molecular Cell·Kam Y J ZhangGideon Bollag
Sep 1, 1994·Acta Crystallographica. Section D, Biological Crystallography·UNKNOWN Collaborative Computational Project, Number 4
Dec 4, 2004·Structure·Graeme L CardKam Y J Zhang
Jul 5, 2005·Bioorganic & Medicinal Chemistry Letters·Helmut HaningErwin Bischoff
Jul 21, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Neal Lemon, Denise Manahan-Vaughan
Sep 14, 2006·Pharmacological Reviews·Andrew T Bender, Joseph A Beavo
Nov 30, 2007·The Journal of Organic Chemistry·Zhao-Kui WanTarek S Mansour
Dec 18, 2008·Handbook of Experimental Pharmacology·Thomas Kleppisch, Robert Feil
Jan 9, 2010·Acta Crystallographica. Section D, Biological Crystallography·Vincent B ChenDavid C Richardson
Apr 13, 2010·Acta Crystallographica. Section D, Biological Crystallography·P EmsleyK Cowtan
May 22, 2010·Journal of Computer-aided Molecular Design·Alan R KatritzkyBogdan Draghici
Mar 5, 2011·Frontiers in Neuroscience·Alexandre E Medina
Apr 5, 2011·Acta Crystallographica. Section D, Biological Crystallography·Garib N MurshudovAlexei A Vagin
Dec 1, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Ryoichi KimuraJack H Jhamandas
Apr 2, 2014·Nature Reviews. Drug Discovery·Donald H MauriceVincent C Manganiello
Jan 1, 1997·Methods in Enzymology·Zbyszek Otwinowski, Wladek Minor

❮ Previous
Next ❯

Citations

Apr 3, 2016·The International Journal of Neuropsychopharmacology·Pim R A HeckmanJos Prickaerts
Apr 14, 2017·Journal of Medicinal Chemistry·Brian DyckAli Tabatabaei
Mar 4, 2018·CNS Neuroscience & Therapeutics·Antonella Cardinale, Francesca R Fusco
Aug 5, 2017·Expert Opinion on Investigational Drugs·Jos PrickaertsArjan Blokland
Jul 22, 2018·Circulation·Toru HashimotoDavid A Kass
Sep 2, 2019·Molecular Neurobiology·Jose A Morales-GarciaAna Perez-Castillo
Sep 15, 2017·British Journal of Pharmacology·Makhala Michell KhammyJacob Nielsen
Aug 8, 2019·Nature Reviews. Drug Discovery·George S BaillieMichy P Kelly
Feb 23, 2019·Frontiers in Molecular Neuroscience·Susan McQuownMarco Peters
Jan 8, 2021·European Journal of Medicinal Chemistry·Nathalia Fonseca NadurArthur Eugen Kümmerle
Sep 20, 2019·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Seyed Mohammad NabaviMohammad Hosein Farzaei
Mar 18, 2020·Journal of Medicinal Chemistry·Benjamin M JohnsonNicholas A Meanwell
Mar 7, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Xuefei LiZhude Tu
Jun 14, 2020·Current Topics in Medicinal Chemistry·Mayasah Y Al-Nema, Anand Gaurav
Nov 27, 2019·Molecular and Cellular Neurosciences·Jennifer J O'BrienJoseph P Hendrick
Apr 26, 2021·Pharmacology & Therapeutics·Arun SamiduraiRakesh C Kukreja
May 19, 2021·European Journal of Clinical Investigation·Dony YugoYi-Jen Chen
May 28, 2021·Journal of Medicinal Chemistry·Jiyun SunSteven H Liang
Jun 19, 2021·Journal of Medicinal Chemistry·Yinuo WuHai-Bin Luo
Aug 4, 2021·Journal of Neuroscience Methods·Pierre VincentSégolène Bompierre
Jan 25, 2018·Journal of Medicinal Chemistry·Yinuo WuHai-Bin Luo
Apr 25, 2020·Journal of Medicinal Chemistry·Lewis D PenningtonIngo Muegge
Jun 20, 2018·Journal of Medicinal Chemistry·Dean G Brown, Jonas Boström
Jun 9, 2021·The Journal of Pharmacology and Experimental Therapeutics·Keivan GolshiriAnton J M Roks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.